Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19752012 | 0.81 | UHRF1 (0.35) | UHRF1PDK2PDK4DRD2DRD1 | |
| SCHEMBL1600410 | 0.79 | ALOX5 (0.32) | ALOX5 | |
| SCHEMBL15334499 | 0.71 | HTR1A (0.36) | PDK2DRD2DRD1SLC6A2SLC6A4 | |
| SCHEMBL6220371 | 0.71 | UHRF1 (0.47) | UHRF1 | |
| SCHEMBL21223232 | 0.69 | GRM5 (0.41) | PDK2PDK4DRD2DRD1METAP2 | |
| SCHEMBL7923006 | 0.69 | HTR2C (0.33) | UHRF1PDK2PDK4 | |
| SCHEMBL25693008 | 0.67 | GRM5 (0.52) | DRD2DRD1 | |
| SCHEMBL14931524 | 0.67 | GRM5 (0.52) | DRD2DRD1 | |
| SCHEMBL20153299 | 0.66 | UHRF1 (0.40) | UHRF1ALOX5 | |
| SCHEMBL279310 | 0.64 | UHRF1 (0.43) | UHRF1DRD2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| US-9701660-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE S.A. (CH) | 2017-07-11 | — | — | US | disclosed |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | AC IMMUNE S.A. (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | AC IMMUNE S.A. (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8916590-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE SA (CH) | 2014-12-23 | — | — | US | disclosed |
| US-8916590-B2 | 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system | AC IMMUNE SA (CH) | 2014-12-23 | — | — | US | disclosed |
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | AC IMMUNE S.A. (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | AC IMMUNE S.A. (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092537-A1 | 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System | APP, CLN6, DPYSL2 | UHRF1 4417/4885PDK2 1853/4885PDK4 1493/4885 |
| US-20150023950-A1 | 2,6-Diaminopyridine Compounds Suitable for Treating Diseases Associated with Amyloid or Amyloid-Like Proteins or for Treating or Preventing Ocular Diseases or Conditions Associated with a Pathological Abnormality/Change in the Tissue of the Visual System | APP, CLN6, DPYSL2 | UHRF1 4417/4885PDK2 1853/4885PDK4 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.